FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development

Targeting FLT3 mutations in AML: review of current knowledge and evidence

(2019) Naval Daver et al.   LEUKEMIA

Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms

(2019) Haijiao Zhang et al.   Nature Communications

Clonal selection with Ras pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia

(2019) Christine M. McMahon et al.   Cancer Discovery

Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial

(2019) Jorge E Cortes et al.   LANCET ONCOLOGY

Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML

(2019) Alexander E. Perl et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 2b study of two dosing regimens of quizartinib monotherapy in FLT3-ITD mutated, relapsed or refractory AML

(2018) Jorge E. Cortes et al.   BLOOD

Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial

(2018) Jorge Cortes et al.   LANCET ONCOLOGY

Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 study

(2018) Yasuhiko Harada et al.   LEUKEMIA RESEARCH

Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells

(2018) Nimitha R Mathew et al.   NATURE MEDICINE

Clinical significance of ASXL2 and ZBTB7A mutations and C-terminally truncated RUNX1-RUNX1T1 expression in AML patients with t(8;21) enrolled in the JALSG AML201 study

(2018) Naomi Kawashima et al.   ANNALS OF HEMATOLOGY

Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia

(2017) Masamichi Mori et al.   INVESTIGATIONAL NEW DRUGS

Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study

(2017) Alexander E Perl et al.   LANCET ONCOLOGY

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

(2017) Richard M. Stone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor

(2016) Lauren Y. Lee et al.   BLOOD

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

(2016) Hartmut Döhner et al.   BLOOD

Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups

(2016) M. R. Luskin et al.   BLOOD

Comprehensive mutational profiling of core binding factor acute myeloid leukemia

(2016) N. Duployez et al.   BLOOD

FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia

(2016) Elie Traer et al.   CANCER RESEARCH

Genomic Classification and Prognosis in Acute Myeloid Leukemia

(2016) Elli Papaemmanuil et al.   NEW ENGLAND JOURNAL OF MEDICINE

DNMT3A Haploinsufficiency Transforms FLT3ITD Myeloproliferative Disease into a Rapid, Spontaneous, and Fully Penetrant Acute Myeloid Leukemia

(2016) S. E. Meyer et al.   Cancer Discovery

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

(2015) Christoph Röllig et al.   LANCET ONCOLOGY

Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia

(2015) I-K Park et al.   LEUKEMIA

Inhibition of c-Kit by tyrosine kinase inhibitors

(2014) A. Galanis et al.   HAEMATOLOGICA

Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients

(2014) R Kihara et al.   LEUKEMIA

Crenolanib is a selective type I pan-FLT3 inhibitor

(2014) C. C. Smith et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target

(2013) I.-K. Park et al.   BLOOD

Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants

(2013) A. Galanis et al.   BLOOD

Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia

(2013)   NEW ENGLAND JOURNAL OF MEDICINE

Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia

(2012) Catherine C. Smith et al.   NATURE

Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia

(2012) Jay P. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo

(2011) T. Sato et al.   BLOOD

Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

(2011) M. Levis et al.   BLOOD

Cell Signaling by Receptor Tyrosine Kinases

(2010) Mark A. Lemmon et al.   CELL

Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia

(2010) Farhad Ravandi et al.   JOURNAL OF CLINICAL ONCOLOGY

Drug resistance in mutant FLT3-positive AML

(2010) E Weisberg et al.   ONCOGENE

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)

(2009) P. P. Zarrinkar et al.   BLOOD

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

(2009) H. Dohner et al.   BLOOD

A quantitative analysis of kinase inhibitor selectivity

(2008) Mazen W Karaman et al.   NATURE BIOTECHNOLOGY

Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia

(2008) Richard F. Schlenk et al.   NEW ENGLAND JOURNAL OF MEDICINE